Sanofi pumps up animal health in India with Dosch deal; Mylan pulls painkillers on potency worries;

@FiercePharma: Judge thwarts Endo's effort to block non-tamper-resistant copies of Opana ER. FDA still might, tho. More | Follow @FiercePharma

> Sanofi ($SNY) plans to beef up its animal health business Merial with the acquisition of India-based Dosch Pharmaceuticals' veterinary business. Report

> Allergan ($AGN) wrapped up its $350 million buyout of dermatology drugmaker Skin Medica. Report

> Mylan ($MYL) pulled three lots of painkillers, including the opioid Vicodin, because of worries that tablets were too large and too potent; the drugs were made by contract manufacturer Qualitest. Report

> Lundbeck's stock may have taken a plunge, but that probably doesn't make it a takeover target, because it's 70% owned by a family foundation. Report

> Orion settled a lawsuit with Mylan, granting the generics maker the right to sell a copy of its Parkinson's drug Comtan in April 2013 at the earliest. Report

> The FDA met with state health officials to discuss heightened oversight of compounding pharmacies, which have been in the spotlight since a deadly meningitis outbreak began. Report (sub. req.)

> Morningstar analysts tapped several pharma stocks as favorites for their dividend yields, including GlaxoSmithKline ($GSK), Eli Lilly ($LLY) and Novartis ($NVS). Report

Medical Device News

 @FierceMedDev: DioGenix Series B funds crucial trial for MS Dx. Story | Follow @FierceMedDev

@MarkHFierce: A Novartis subsidiary is licensing Trovagene's find that a certain protein, found in urine, can indicate leukemia. News | Follow @MarkHFierce

 @DamianFierce: Privately held CardiacAssist is targeting the heart pump market after getting FDA OK for a pivotal trial. More | Follow @DamianFierce

> Covidien's catheter posts sterling 5-year results. Report

> Analyst report: Med Tech M&A and restructuring to surge in 2013. Article

Biotech News

 @FierceBiotech: Nuron Biotech bags $80M deal to back vaccines portfolio, PhIII multiplesclerosis drug work. Story | Follow @FierceBiotech

@JohnCFierce: Tredaptive failure likely to leave a mark at Merck, which spends more than $8B a year on R&D. This could trigger a reorg. News | Follow @JohnCFierce

@RyanMFierce: Biogen is teaming up on ALS research w/ experts @ Yale Harvard & Columbia, committing $10M+, as its ALS rx is in P3. Release | Follow @RyanMFierce

> Roche's sweet spot: The $6B-$7B acquisition deal. Item

> Investors gamble $75M on Ultragenyx's plan to jump-start rare-disease player. Report

Pharma Manufacturing News

> Hot for fish oil, BASF expands plant, pursues Pronova. News

> India API makers complain about cheap Chinese imports. Story

Vaccines News

 @AlisonBFierce: India is cruising along in the vaccines market. A WHO clearance will hoist the country's vaccine exports. More | Follow @AlisonBFierce

> WHO clearance to hoist Indian vaccine exports. Report

> GSK teams with GlycoVaxyn to develop anti-bacterial vaccines. Article

> U.N. contemplates ban on vaccine preservative. News

> FDA approves GSK's quadrivalent flu vaccine. Story

> Georgia State scientists investigate universal flu vaccine. More

And Finally ... Bouts of deep concentration à la Sherlock Holmes, even in small doses, may make us better multitaskers. Report (sub. req.)

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.